Stay updated on Pembrolizumab in 1st Line NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab in 1st Line NSCLC Clinical Trial page
- Check6 days agoChange DetectedA new publication citation has been added in Publications for the KEYNOTE-189 Japan extension study, with authors and journal details; the entry also indicates a version revision from v3.5.3 to v3.5.4.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page shows an updated revision label 'Revision: v3.5.3' replacing the previous 'Revision: v3.5.2', indicating a software release rather than a change to the study data.SummaryDifference0.0%

- Check27 days agoNo Change Detected
- Check35 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check56 days agoChange DetectedThe page now displays Revision: v3.5.0, replacing the previous Revision: v3.4.3.SummaryDifference0.0%

- Check70 days agoChange DetectedRevision: v3.4.3 has been added, replacing the previous v3.4.2. This is a minor UI/version update and does not change study details or user interactions on the page.SummaryDifference0.0%

- Check99 days agoChange DetectedRevision: v3.4.2 is now shown; notices about government funding lapses and Revision: v3.4.1 respectively have been removed.SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab in 1st Line NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.